Hepatorenal syndrome and its treatment today

被引:14
作者
Gentilini, P [1 ]
La Villa, G [1 ]
Casini-Raggi, V [1 ]
Romanelli, RG [1 ]
机构
[1] Univ Florence, Sch Med, Inst Internal Med, I-50134 Florence, Italy
关键词
ascites; hepatorenal syndrome; liver cirrhosis; plasma expanders; renal function;
D O I
10.1097/00042737-199909000-00021
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The pathogenesis of ascites, a severe and the most frequent complication during cirrhosis, is still not completely understood, but present evidence indicates that portal hypertension principally triggers renal sodium and water retention. Ascites is associated with profound disturbances of splanchnic and systemic haemodynamics, which in turn may influence renal function, Within the kidney the balance between vasoconstricting and vasodilating factors is critical for the maintenance of renal function. As the disease progresses, vasoconstricting factors (mainly angiotensin II, catecholamines, thromboxane, leucotrienes and endothelins) prevail, probably due to the exhaustion of the vasodilating renal autacoid system (mainly prostaglandins). In this setting, vasoconstriction of the intrarenal vascular system induces marked and often irreversible sodium and water retention, leading to refractory ascites, a progressive rise in plasma creatinine levels and reduction of renal clearances (hepatorenal syndrome, MRS). This persistent renal hypoxia may also favour the occurrence of tubular damage due to several causes. A careful therapeutic approach is first based on sequential diuretic treatment land the addition of adequate plasma expansion with human albumin for patients with diuretic resistant ascites), which may lead to control of ascites for years. However, when HRS occurs, all the proposed treatments (such as paracentesis, administration of renal vasodilators, systemic vasoconstrictors, calcium channel antagonists, TIPS, surgical portosystemic shunts) have been shown to moderately or temporarily improve renal function only, leaving liver transplantation as the only choice of treatment for patients, fur J Gastroenterol Hepatol 11:1061-1065 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:1061 / 1065
页数:5
相关论文
共 60 条
[1]  
ALKAREEMY EA, 1988, CLIN RADIOL, V53, P44
[2]   Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis [J].
Arroyo, V ;
Gines, P ;
Gerbes, AL ;
Dudley, FJ ;
Gentilini, P ;
Laffi, G ;
Reynolds, TB ;
RingLarsen, H ;
Scholmerich, J .
HEPATOLOGY, 1996, 23 (01) :164-176
[3]   RENIN, ALDOSTERONE AND RENAL HEMODYNAMICS IN CIRRHOSIS WITH ASCITES [J].
ARROYO, V ;
BOSCH, J ;
MAURI, M ;
VIVER, J ;
MAS, A ;
RIVERA, F ;
RODES, J .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1979, 9 (01) :69-73
[4]   DISTURBED VOLUME HOMEOSTASIS IN PATIENTS WITH CIRRHOSIS OF THE LIVER [J].
BETTER, OS ;
SCHRIER, RW .
KIDNEY INTERNATIONAL, 1983, 23 (02) :303-311
[5]   ACUTE-RENAL-FAILURE [J].
BRADY, HR ;
SINGER, GG .
LANCET, 1995, 346 (8989) :1533-1540
[6]   EFFECT OF AN ENDOTHELIN-RECEPTOR ANTAGONIST ON ISCHEMIC ACUTE-RENAL-FAILURE [J].
CHAN, L ;
CHITTINANDANA, A ;
SHAPIRO, JI ;
SHANLEY, PF ;
SCHRIER, RW .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (01) :F135-F138
[7]  
Cohn J N, 1970, Med Ann Dist Columbia, V39, P1
[8]   SURVIVAL AND PROGNOSTIC INDICATORS IN COMPENSATED AND DECOMPENSATED CIRRHOSIS [J].
DAMICO, G ;
MORABITO, A ;
PAGLIARO, L ;
MARUBINI, E .
DIGESTIVE DISEASES AND SCIENCES, 1986, 31 (05) :468-475
[9]   RENAL FAILURE IN PATIENT WITH CIRRHOSIS - ROLE OF ACTIVE VASOCONSTRICTION [J].
EPSTEIN, M ;
BERK, DP ;
HOLLENBERG, NK ;
ADAMS, DF ;
CHALMERS, TC ;
ABRAMS, HL ;
MERRILL, JP .
AMERICAN JOURNAL OF MEDICINE, 1970, 49 (02) :175-+
[10]  
Epstein M, 1988, KIDNEY LIVER DISEASE, P89